TRPV2 and myeloid sarcoma: Studies by Hainz et al. [14,15,16] demonstrated that probenecid, a pannexin-1 antagonist, but also a specific TRPV2 agonist [1], improves the outcome in two experimental mouse models of multiple sclerosis (MS): in the experimental autoimmune encephalomyelitis (EAE) model, it is capable of preventing and arresting the progression of clinical symptoms and promoting oligodendrocyte proliferation [14,15] and in the cuprizone model of demyelination/remyelination, it reduces demyelination [16].